Molina-Infante J, Santolaria S, Sanders D S, Fernández-Bañares F
Department of Gastroenterology, Hospital San Pedro de Alcantara, Caceres, Spain.
Aliment Pharmacol Ther. 2015 May;41(9):807-20. doi: 10.1111/apt.13155. Epub 2015 Mar 6.
Noncoeliac gluten sensitivity (NCGS) is a controversial emerging disorder. Despite reported symptoms related to the ingestion of gluten, NCGS remains a diagnosis based on the exclusion of coeliac disease, given the absence of reliable biomarkers.
To evaluate the prevalence, diagnostic exclusion of coeliac disease and the efficacy of a gluten-free diet (GFD) for NCGS patients.
A PubMed search was performed up to December 2014. According to consensus diagnostic criteria, NCGS was defined as self-reported gluten intolerance, negative coeliac serology and absence of villous atrophy. Studies evaluating the impact of a GFD on patients with irritable bowel syndrome (IBS) were also included.
Prevalence rates of NCGS (0.5-13%) differed widely. Seventeen studies, including 1561 patients (26 children), met the inclusion criteria for NCGS. HLA haplotypes could not be linked to histology [normal or lymphocytic enteritis (LE)] in 1123 NCGS patients. HLADQ2/DQ8 haplotypes were present in 44% of NCGS patients. After advanced diagnostic techniques in 189 NCGS patients combining LE and HLADQ2/DQ8 haplotypes, 39 (20%) were reclassified as coeliac disease. There was a higher than expected family history of coeliac disease and autoimmune disorders in NCGS patients. A GFD resulted in variable results for variable, but significantly improved stool frequency in HLADQ2 positive diarrhoea-predominant IBS patients.
Prevalence rates for NCGS are extremely variable. A subset of NCGS patients might belong in the so-called 'coeliac-lite' disease. The benefit of a GFD for NCGS patients is currently controversial. HLADQ2 positive diarrhoea-type IBS patients might gain symptom improvement from a GFD.
非乳糜泻性麸质敏感(NCGS)是一种存在争议的新出现的病症。尽管有报告称摄入麸质会出现相关症状,但由于缺乏可靠的生物标志物,NCGS仍然是一种基于排除乳糜泻的诊断。
评估NCGS患者的患病率、乳糜泻的诊断排除情况以及无麸质饮食(GFD)的疗效。
截至2014年12月进行了PubMed检索。根据共识诊断标准,NCGS被定义为自我报告的麸质不耐受、乳糜泻血清学阴性且无绒毛萎缩。还纳入了评估GFD对肠易激综合征(IBS)患者影响的研究。
NCGS的患病率(0.5 - 13%)差异很大。17项研究,包括1561名患者(26名儿童),符合NCGS的纳入标准。在1123名NCGS患者中,HLA单倍型与组织学[正常或淋巴细胞性肠炎(LE)]无关联。44%的NCGS患者存在HLADQ2/DQ8单倍型。在189名结合了LE和HLADQ2/DQ8单倍型的NCGS患者中采用先进诊断技术后,39名(20%)被重新分类为乳糜泻。NCGS患者中乳糜泻和自身免疫性疾病的家族史高于预期。GFD对不同患者产生了不同结果,但在HLADQ2阳性、以腹泻为主型的IBS患者中,大便频率有显著改善。
NCGS的患病率变化极大。一部分NCGS患者可能属于所谓的“轻型乳糜泻”疾病。目前,GFD对NCGS患者的益处存在争议。HLADQ2阳性腹泻型IBS患者可能会从GFD中获得症状改善。